Nymox Pharmaceutical Corp. {NASDAQ: NYMX} announced results from the completion of the Company’s U.S. 40 month (18 month outcomes) localised prostate cancer Phase 2 NX03-0040 clinical trial of fexapotide triflutate (NX-1207).
The study successfully met its pre-determined endpoints. Continue reading